# Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

> **NCT02085798** · — · COMPLETED · sponsor: **Celgene** · enrollment: 503 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Leukemia, Myelomonocytic, Chronic

## Interventions

- **OTHER:** Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion

## Key facts

- **NCT ID:** NCT02085798
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-17
- **Primary completion:** 2015-08-31
- **Final completion:** 2018-12-14
- **Target enrollment:** 503 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02085798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02085798, "Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02085798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*